Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?

被引：4
|
作者：
Doki, Y [1 ]
Monden, M [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan
来源：
JOURNAL OF GASTROENTEROLOGY | 2004年 / 39卷 / 12期
关键词：
D O I：
10.1007/s00535-004-1508-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1228 / 1229
页数：2
相关论文
共 50 条
  • [1] Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?
    Yuichiro Doki
    Morito Monden
    Journal of Gastroenterology, 2004, 39 : 1228 - 1229
  • [2] Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
    Zhu, Yunshu
    Yang, Sheng
    Zhou, Shengyu
    Yang, Jianliang
    Qin, Yan
    Gui, Lin
    Shi, Yuankai
    He, Xiaohui
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] VIMENTINE AS A PREDICTIVE MARKER OF PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER PATIENTS
    Bogush, T.
    Dudko, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1408 - 1408
  • [4] Platinum-based transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma
    Ogawa, Kohei
    Kamimura, Kenya
    Suda, Takeshi
    Yokoo, Takeshi
    Sakamaki, Akira
    Abe, Satoshi
    Kamimura, Hiroteru
    Tsuchiya, Atsunori
    Takamura, Masaaki
    Kawai, Hirokazu
    Waguri, Nobuo
    Ishikawa, Toru
    Yamagiwa, Satoshi
    Terai, Shuji
    HEPATOLOGY, 2016, 64 : 652A - 652A
  • [5] ERCC1 Codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy
    Kamikozuru, H.
    Kuramochi, H.
    Hayashi, K.
    Uchida, K.
    Yamamoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy
    Kamikozuru, Hirotaka
    Kuramochi, Hidekazu
    Hayashi, Kazuhiko
    Nakajima, Go
    Yamamoto, Masakazu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 32 (05) : 1091 - 1096
  • [7] Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
    Valenza, Carmine
    Mongillo, Marta
    Boldrini, Laura
    Guidi, Lorenzo
    Farfalla, Alessia
    Malengo, Daniela
    Caruso, Giuseppe
    Lapresa, Mariateresa
    Parma, Gabriella
    Biagioli, Elena
    Curigliano, Giuseppe
    Colombo, Nicoletta
    Visconti, Maria Vittoria
    Katrini, Jalissa
    Trapani, Dario
    Derio, Silvia
    GYNECOLOGIC ONCOLOGY, 2025, 194 : 11 - 17
  • [8] Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology
    Minato, Akinori
    Murooka, Kazuki
    Okumura, Yutaka
    Takaba, Tomohisa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Harada, Kenichi
    Fujimoto, Naohiro
    IN VIVO, 2024, 38 (02): : 873 - 880
  • [9] Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy
    Nio, Kenta
    Arita, Shuji
    Isobe, Taichi
    Kusaba, Hitoshi
    Kohashi, Kenichi
    Kajitani, Tatsuhiro
    Tamura, Shingo
    Hirano, Gen
    Mitsugi, Kenji
    Makiyama, Akitaka
    Esaki, Taito
    Ariyama, Hiroshi
    Oda, Yoshinao
    Akashi, Koichi
    Baba, Eishi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 829 - 835
  • [10] Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy
    Kenta Nio
    Shuji Arita
    Taichi Isobe
    Hitoshi Kusaba
    Kenichi Kohashi
    Tatsuhiro Kajitani
    Shingo Tamura
    Gen Hirano
    Kenji Mitsugi
    Akitaka Makiyama
    Taito Esaki
    Hiroshi Ariyama
    Yoshinao Oda
    Koichi Akashi
    Eishi Baba
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 829 - 835
12345